Additionally, in the U.S. alone, these specific medications could generate $70 billion in revenue. That analysis is according to Evan David Seigerman, an analyst at BMO Capital Markets.
As patients begin to understand the efficacy of the medications, particularly as it relates to weight-loss, the demand will begin to rise, according to Fortune.
